CD274 and non-small cell lung carcinoma: Ivonescimab received a breakthrough therapy designation (BTD) from The Center for Drug Evaluation of the China National Medical Products Administration in combination with docetaxel for the treatment of patients with locally advanced or metastatic NSCLC who had been unresponsive to prior PD-L1 inhibitor plus platinum-based doublet chemotherapy.